Navigation Links
ShangPharma Announces Second Quarter 2011 Results
Date:8/22/2011

ories as well as major multinational biotech and pharmaceutical companies' Chinese R&D centers.  In light of the Chinese government's rising support of locally-developed drugs and more R&D investment into China by global pharmaceutical and biotech companies, the Company anticipates its China business will continue to grow and become a larger percentage of total revenues.

Revenue from the Company's top-10 customers increased by 24.4% compared with the same period last year, and accounted for 61.8% of the total revenue compared with 62.6% in the same quarter last year.  The increase in top-10 customers' revenue has further demonstrated our continued efforts and commitments to become preferred business partners with global leading pharmaceutical and biotech companies.  In addition, percentage of revenue from top-10 customers as of total revenue has continued to decrease due to the very strong increase in revenue contribution from China-based clients and increased diversification of the customer base.

Net revenues from full-time-equivalent ("FTE")-based services were $19.7 million, an increase of 26.5% from $15.6 million in the second quarter of 2010, primarily due to an increase in FTE numbers and higher FTE rates.

Net revenues from fee-for-service-based services were $7.8 million, an increase of 24.9% from $6.2 million in the second quarter of 2010.  The rise was primarily driven by the Company's service offerings including discovery biology, preclinical development and newer biologics services. The growth in fee-for-service-based revenues reflects the Company's ability to cross-sell more services to existing customers as well as strong demand from new customers.  The Company also saw strong demand from customers that use multiple services.

Gross profit was $9.1 million, an increase of 23.6% from $7.4 million in the second quarter of 2010, primarily due to the increase in revenues, operational efficie
'/>"/>

SOURCE ShangPharma Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. ShangPharma Corporation Named a Top Ten Chinese Outsourcing Enterprise
2. ShangPharma Announces First Quarter 2011 Results
3. ShangPharma Corp. to Announce Fourth Quarter and Full Year 2010 Financial Results on March 15, 2011
4. Stem Cell Assurance, Inc. Announces Change of Name to BioRestorative Therapies, Inc.
5. Syndax Pharmaceuticals Announces Issuance of EU Patent for Entinostat
6. Regeneron Announces Review of Biologics License Application for EYLEA™ (aflibercept injection) Extended by Three Months by FDA
7. ACMG Announces New Online Live Learning Center: Will Bring Genetics and Genomics Education to Varied Health Professionals
8. Neurologix Announces Second Quarter 2011 Financial Results
9. Bion Announces New U.S. Patent for Phosphorus Removal
10. ViaCyte Announces Executive Management Changes
11. NeoStem Announces the Receipt of Over $1,700,000 in DOD Funding for its VSEL™ Technology Being Developed to Treat Osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... used for detailed studies of what happens on the ... research, among other applications. A group of researchers from ... cell membranes form across a large number of vertical ... the interior of a cell and its surroundings takes ... surface layer that holds the cell together and that ...
(Date:9/2/2014)... 2, 2014  TransCelerate BioPharma Inc. ("TransCelerate") today ... for protecting personal data in Clinical Study Reports ... others. The document describes an approach to apply ... and other related clinical trial documents, and is ... of the TransCelerate CSR Redaction approach is to ...
(Date:9/2/2014)... 2014 Orexigen Therapeutics, Inc. (Nasdaq: ... Trademark Office (PTO) has issued a patent related to ... loss. NB32 is a fixed-dose combination of naltrexone sustained ... No. 8,815,889 claims methods for treating insulin resistance using ... in 2024. If NB32 is approved for use in ...
(Date:9/2/2014)... - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced ... three large odour control systems for waste water treatment plants ... are consistent with the market resurgence in North ... CEO. "After a difficult period of restraint in our core ... sales growth. Our lower cost structure, technology improvements and supply ...
Breaking Biology Technology:Nano-forests to reveal secrets of cells 2TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 2TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 3Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 2Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 3Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 4
... 13 /PRNewswire-Asia/ -- IVT Corporation announced today that,it will demonstrate ... Hong Kong on Nov. 18-19, at Booth F08, and CES ... reducing risk of diseases and,assisting with emergency rescue. , ... It includes: , 1) ...
... Nov. 12 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (Nasdaq:,SSRX) ("3SBio" or ... developing, manufacturing and marketing,biopharmaceutical products, today announced its unaudited ... , , Third Quarter 2009 Financial ... by 35.8% over the third quarter of 2008 to, ...
... AvidBiotics Corp. announced the issuance of foundational ... massive diversity within precisely targeted sites of protein-encoding ... to as Diversity Generating Retroelements (DGR) and patents ... and in Europe (#1,173,995). UCLA and AvidBiotics ...
Cached Biology Technology:IVT will Demo Mobile Health System at GSMA Mobile Asia Congress and CES 2010 23SBio Inc. Announces Unaudited Third Quarter 2009 Results 23SBio Inc. Announces Unaudited Third Quarter 2009 Results 33SBio Inc. Announces Unaudited Third Quarter 2009 Results 43SBio Inc. Announces Unaudited Third Quarter 2009 Results 53SBio Inc. Announces Unaudited Third Quarter 2009 Results 63SBio Inc. Announces Unaudited Third Quarter 2009 Results 73SBio Inc. Announces Unaudited Third Quarter 2009 Results 83SBio Inc. Announces Unaudited Third Quarter 2009 Results 93SBio Inc. Announces Unaudited Third Quarter 2009 Results 103SBio Inc. Announces Unaudited Third Quarter 2009 Results 113SBio Inc. Announces Unaudited Third Quarter 2009 Results 123SBio Inc. Announces Unaudited Third Quarter 2009 Results 133SBio Inc. Announces Unaudited Third Quarter 2009 Results 143SBio Inc. Announces Unaudited Third Quarter 2009 Results 153SBio Inc. Announces Unaudited Third Quarter 2009 Results 163SBio Inc. Announces Unaudited Third Quarter 2009 Results 173SBio Inc. Announces Unaudited Third Quarter 2009 Results 183SBio Inc. Announces Unaudited Third Quarter 2009 Results 193SBio Inc. Announces Unaudited Third Quarter 2009 Results 203SBio Inc. Announces Unaudited Third Quarter 2009 Results 21AvidBiotics Corp. Granted Key U.S. and European Patents on Unique Protein Modification Platform 2
(Date:9/2/2014)... history of scientific research on mountain ecosystems, looks ... and sets an agenda for biodiversity conservation throughout ... gloom and mountain glory revisited: A survey of ... appears online in the Journal of Mountain ... Tufts University, Jodi A. Hilty of the Wildlife ...
(Date:9/2/2014)... always true that digital distribution of media will ... means, at least when file sizes are large. ... in Yale,s Journal of Industrial Ecology ... for consoles such as PlayStation3. Researchers found that ... greenhouse gas emissions than game files downloaded over ...
(Date:9/2/2014)... R.I. [Brown University] It,s hard to comprehend how ... world has become without knowing what it was before ... pre-human rate was 10 times lower than scientists had ... times worse. , Extinctions are about 1,000 times more ... people came along. The explanation from lead author Jurriaan ...
Breaking Biology News(10 mins):An uphill climb for mountain species? 2An uphill climb for mountain species? 3Extinctions during human era worse than thought 2Extinctions during human era worse than thought 3
... A University of Utah biologist and an international research team ... hope for new ways to attack the major pest, which ... The voracious mites, which technically are not insects, can ... The mites, newly revealed and sequenced genome contains a variety ...
... of Illinois at Chicago College of Medicine describe for ... checkpoint enzymes that must be chemically modified to enable ... thought to play a key role in cancer and ... Nature Structural and Molecular Biology . Telomeres are ...
... recent opening of its new Biomolecular Labeling Laboratory, the ... one of a small handful of facilities in the ... isotopes to make them easier to analyze. The new ... in biomedical fields who also want to take advantage ...
Cached Biology News:Big pest, small genome 2Big pest, small genome 3Big pest, small genome 4UIC study identifies a key molecular switch for telomere extension by telomerase 2Tags? We're it. NIST opens new 'biolabeling' research facility 2
... is a very sensitive immunohistochemical tool for ... both anti-von Willebrand Factor and anti-CD31 primary ... of species. This AP kit provides a ... frozen and paraffin-embedded sections in human (both ...
... Applied Biosystems and MDS Sciex ... System, a high performance hybrid triple ... the drug discovery, drug development or ... (LIT) Technology from the leaders in ...
... 18 amino acid synthetic peptide whose sequence corresponds to residues 1-18 ... (amino to carboxy terminus): M(1) - A - S - A ... S - P - R - D - A - A ... be used for neutralization and control experiments with the polyclonal antibody ...
... is a fixative useful for routine procedures. ... is stable and will decalcify small bone ... can be stained successfully with most stains, ... stabilizes red blood cell membranes and cosinophil ...
Biology Products: